

Hepatitis B virus targets lipid transport pathways to infect hepatocytes

Knud Esser, Xiaoming Cheng, Jochen Wettengel, Julie Lucifora, Lea Hansen-Palmus, Katharina Austen, Armando A.R. Suarez, Sarah Heintz, Barbara Testoni, Firat Nebioglu, et al.

▶ To cite this version:

Knud Esser, Xiaoming Cheng, Jochen Wettengel, Julie Lucifora, Lea Hansen-Palmus, et al.. Hepatitis B virus targets lipid transport pathways to infect hepatocytes. Cellular and Molecular Gastroenterology and Hepatology, In press, 10.1016/j.jcmgh.2023.03.011. hal-04069375

HAL Id: hal-04069375 https://hal.science/hal-04069375

Submitted on 14 Apr 2023 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Hepatitis B virus targets lipid transport pathways to infect
2	hepatocytes
3	
4	Knud Esser* ¹ , Xiaoming Cheng* ¹ , Jochen M. Wettengel* ¹ , Julie Lucifora ^{2,3} , Lea Hansen-
5	Palmus ¹ , Katharina Austen ¹ , Armando A. R. Suarez ³ , Sarah Heintz ³ , Barbara Testoni ³ , Firat
6	Nebioglu ⁴ , Minh Tu Pham ⁴ , Shangqing Yang ⁴ , Alma Zernecke ⁵ , Dirk Wohlleber ^{6,7} , Marc
7 8	Ringelhan ^{7,8} , Mathias Broxtermann ¹ , Daniel Hartmann ⁹ , Norbert Hüser ⁹ , Julia Mergner ¹⁰ , Andreas Pichlmair ^{1,7,10} , Wolfgang E. Thasler ¹¹ , Mathias Heikenwalder ¹ , Georg Gasteiger ¹ ,
8 9	Andreas Blutke ¹² , Axel Walch ¹² , Percy A. Knolle ^{6,7} , Ralf Bartenschlager ^{4,7,13} and Ulrike
10	Protzer ^{1,7}
11	*Authors contributed equally to the work
12	
13 14	¹ Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Trogerstr. 30, 81675 Munich, Germany
15	² INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France.
16	University of Lyon, Université Claude-Bernard (UCBL), Lyon, France.
17 18	³ CIRI—Centre International de Recherche en Infectiologie, Inserm, U1111, Univ Lyon, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS Lyon
19 20 21	⁴ Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Im Neuenheimer Feld 344, 69120 Heidelberg, Germany
22	⁵ Institute of Experimental Biomedicine, University Hospital Würzburg, Josef-Schneider-Str. 2,
23	Würzburg 97080, Germany
24 25 26	⁶ Institute of Molecular Immunology and Experimental Oncology, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Ismaninger Str. 22, 81675 Munich, Germany
27	⁷ German Center for Infection Research (DZIF), Munich and Heidelberg partner sites
28 29	⁸ 2nd Medical Department, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Ismaninger Str. 22, 81675 Munich, Germany
30 31	⁹ Department of Surgery, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Ismaninger Str. 22, 81675 Munich Germany
32 33	¹⁰ Bavarian Center for Biomolecular Mass Spectrometry at Klinikum rechts der Isar (BayBioMS@MRI), TUM, Munich, Germany

- ¹¹Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Grosshadern
- 35 Hospital, Ludwig Maximilians University, Nussbaumstr. 20, 80336 Munich, Germany
- ¹²Institute of Pathology, Helmholtz Zentrum München, Ingolstädter Landstr. 1, 85764 Neuherberg,
- 37 Germany
- ¹³Division Virus-Associated Carcinogenesis, German Cancer Research Center (DKFZ), Im
- 39 Neuenheimer Feld 280, 69120 Heidelberg, Germany
- 40
- 41 Short Title: HBV targets the cholesterol transport
- Author Contributions: Study concept and design: KE, XC, PAK, RB, UP; Acquisition of
 data: KE, XC, JL, LHP, KA, DW, MR, JMW, FM, MTP, SY, MB, AB;
 Analysis and interpretation of data: KE, XC, JL, JMW, DW, MR, MG, KA,
 MH, GG, AW, PAK, UP; Administrative, technical, or material support:
 DH, NH, AZ, WET; Obtained funding: MH, PAK, RB, UP; Drafting of the
 manuscript: KE, XC, PAK, UP; Critical revision of the manuscript for
 important intellectual content: all authors.
- Grant support: This study was supported by grants from the Deutsche 49 50 Forschungsgemeinschaft (project number 272983813 – TRR 179), projects TP 05 to PK, TP 06 to MH, TP09 to RB, TP11 to AP and TP 14 51 to UP, the German Center for Infection Research (DZIF) project 05.806 52 and by the European Union's Horizon 2020 research and innovation 53 54 programme under grant agreement 848223 (VIROFIGHT consortium). BT, AARS and SH were supported by public grants overseen by the 55 56 French National Research Agency (ANR) as part of the second "Investissements d'Avenir" program (reference: ANR-17-RHUS-0003) 57 and by the European Union (grant EU H2020-847939-IP-cure-B). 58
- 59 Correspondence: Knud Esser, PhD and Prof. Ulrike Protzer, MD 60 Institute of Virology, TUM / Helmholtz Zentrum München Trogerstr. 30, D-81675 Munich, Germany 61 62 protzer@tum.de; protzer@helmholtz-muenchen.de; knud.esser@tum.de +49 89 4140 6821; +49 211 810 6025 63 64 Disclosure: The authors declare no conflict of interest relevant to this manuscript 65 and the data reported Word Count: 66 summary: 241 words; synopsis: 39 words;
- 67 main document text: 4367 words; 40 references

68 Writing assistance: None

69	Data transparenc	cy:all data, analytical methods and study materials will be made available to
70		other researchers upon reasonable request to the corresponding author
71	Abbreviations:	Apo: apolipoprotein
72		BODIPY: dipyrrometheneboron difluoride
73		cccDNA: covalently closed circular DNA
74		CMFDA: chloromethylfluorescein diacetate
75		DNA: deoxyribonucleic acid
76		DC-SIGN: dendritic cell-specific intercellular adhesion molecule-3-
77		grabbing nonintegrin
78		HBeAg: HBV e antigen
79		HBsAg: HBV surface antigen
80		HBV: Hepatitis B virus
81		HDL: high density lipoprotein
82		HSPG: heparan sulfate proteoglycan
83		IDL: intermediate density lipoprotein
84		LAMP 1: lysosomal-associated membrane protein 1
85		LDL: low density lipoprotein
86		LRP: LDL-receptor related protein
87		LSEC: liver sinusoidal endothelial cells
88		L-SIGN: liver/lymph node-specific intercellular adhesion molecule-3-
89		grabbing nonintegrin
90		NBD: nitrobenzoxadiazole
91		NPC-1: Niemann-Pick C1
92		NTCP: sodium taurocholate cotransporting polypeptide
93		Rab 11: Ras-related protein Rab-11A
94		TG: triglyceride
95		VLDL: very low density lipoprotein
96		VP: viral particle
97		

98 Synopsis (40 words):

99 A single HBV virion suffices to infect an individual indicating that it hijacks a physiological

100 pathway targeting hepatocytes. HBV associates with lipoproteins to access the perisinusoidal

101 space or to follow the physiological cholesterol transport pathway to hepatocytes via 102 macrophages.

103

104 Graphical Abstract: Model for HBV host cell targeting to achieve hepatocyte infection.

- 105
- 106

<sup>ApoE: apolipoprotein E; ApoA1: apolipoprotein A1; EE: early endosome; HSPG: heparan sulfate
proteoglycans; KC: liver macrophages (Kupffer cell); LDL-R: LDL-receptor; LE: late endosome; LSEC:
liver sinusoidal endothelial cell; Lys: lysosome; NPC1: Niemann Pick Typ C 1 protein; NTCP: sodium
taurocholate cotransporting polypeptide; RE: recycling endosome; SC: Stellate cell; TRL: triglyceriderich lipoprotein remnant</sup>

112 Abstract (260 words)

Background and aims: A single hepatitis B virus (HBV) particle is sufficient to establish chronic infection of the liver after intravenous injection, suggesting that the virus targets hepatocytes via a highly efficient transport pathway. We therefore investigated whether HBV utilizes a physiological liver-directed pathway that supports specific host-cell targeting *in vivo*.

Methods: We established an *ex vivo* system of perfused human liver tissue that recapitulates the liver physiology to investigate HBV liver targeting. This model allowed us to investigate virus-host cell interactions in a cellular microenvironment mimicking the *in vivo* situation.

120 **Results:** HBV was rapidly sequestered by liver macrophages within one hour after a virus 121 pulse, but was detected in hepatocytes only after 16 hours. We found that HBV associates with lipoproteins. Electron- and immunofluorescence microscopy corroborated a co-122 localization in recycling endosomes within peripheral and liver macrophages. Importantly, 123 124 recycling endosomes accumulated HBV and cholesterol, followed by transport of HBV back to the cell surface along the cholesterol efflux pathway. To reach hepatocytes as final target cells, 125 HBV was able to utilise the hepatocyte-directed cholesterol transport machinery of 126 macrophages. 127

Conclusions: Our results propose that HBV by binding to liver targeted lipoproteins and utilizing the reverse cholesterol transport pathway of macrophages hijacks the physiological lipid transport pathways to the liver to most efficiently reach its target organ. This may involve trans-infection of liver macrophages and result in deposition of HBV in the perisinusoidal space from where HBV can bind its receptor on hepatocytes.

133

134 Keywords

135 Transcytosis, trans-infection, liver targeting, lipoprotein metabolism

137 Introduction

138 Hepatitis B virus (HBV) belongs to the family hepadnaviridae and is a highly infectious and organ specific pathogen. Currently over 290 million humans worldwide are chronically infected 139 140 with HBV and at high risk to develop liver cirrhosis or hepatocellular carcinoma (www.who.int/mediacentre/factsheets/fs204/en/). The successful dissemination of HBV within 141 142 the human population relies mainly on vertical transmission that allows an immune escape of 143 the virus or sexual transmission that requires an efficient transmission at a low infection dose. 144 HBV infectivity indeed is extraordinarily high, and during experimental infection in chimpanzees, a single virion was reported to suffice to establish HBV infection¹. Recently, the 145 sodium taurocholate cotransporting polypeptide (NTCP) expressed on the basolateral 146 membrane i.e. side of hepatocytes facing the liver sinusoid has been identified as a crucial 147 receptor². Following initial attachment of HBV virion to heparan sulfate proteoglycans 148 (HSPG)^{3,4}, that are typically found in the space of Dissé between liver sinusoidal endothelial 149 cells and hepatocytes, NTCP binds the myristoylated N-terminal part of the large HBV surface 150 protein. How HBV can gain access to the liver and to its receptor on the hepatocyte so 151 152 efficiently, however, is not understood.

153 In the liver, hepatocytes are lined and shielded from pathogens and gut-derived toxins by a layer of fenestrated liver sinusoidal endothelial cells (LSEC), on top of which Kupffer cells are 154 located representing the largest population of organ-resident macrophages in the body. For 155 some hepatotropic pathogens there is evidence that sinusoidal liver cells contribute to 156 hepatocyte infection⁵. Hepatitis C virus (HCV) has been shown to be captured by the C-type 157 lectin dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) 158 and a liver/lymph node-specific version (L-SIGN)⁶, that both are present on LSEC⁷. Cells 159 expressing DC-SIGN and L-SIGN can trans-infect hepatocytes with HCV⁸ and LSEC can 160 promote HCV infection in a paracrine fashion⁹. The duck analogue of HBV was reported to be 161 taken up preferentially by LSEC and not by hepatocytes in vivo¹⁰ suggesting that LSEC remove 162 duck HBV from the circulation and subsequently deliver it to hepatocytes. 163

For plasmodium sporozoites, intravital microscopy of mouse liver showed sporozoite 164 165 transmigration through Kupffer cells and LSEC escaping lysosomal compartments before entering hepatocytes^{11,12}. Thus, there is evidence that pathogens may exploit trans-cellular 166 167 transport processes to target hepatocytes in a similar fashion as molecules like transferrin or ceruloplasmin transporting iron and copper, respectively. We recently showed that HBV 168 infection of hepatocytes is significantly reduced when lipases are inhibited, and found a 169 reduced hepatic virus uptake *in vivo* if apolipoprotein (Apo) E is lacking¹³. These data are in 170 171 line with the finding that ApoE-specific antibodies inhibit HBV infection¹⁴. This indicated a transport pathway employed by HBV along with lipoproteins to efficiently target hepatocytes. 172

The liver plays a key role in lipid metabolism. It takes up and oxidizes triglycerides (TG), 173 converts excess carbohydrates and proteins into fatty acids and TG to provide energy and 174 synthesizes cholesterol, phospholipids and Apo. Furthermore, it secretes cholesterol into bile 175 176 or converts it to bile salts. TG and cholesterol are hydrophobic neutral lipids that travel within the water-based blood embedded within lipoprotein particles containing Apo. Lipoprotein 177 particles are divided by their density relative to surrounding water into ultra-low density 178 chylomicrons, very low (VLDL), intermediate (IDL), low (LDL) and high (HDL) density 179 180 lipoproteins.

Ultra-low density chylomicrons transport lipids absorbed from the intestine to adipose, cardiac, 181 and skeletal muscle tissue, where their TG components are hydrolyzed by lipoprotein lipases 182 and released. When most of the TG have been hydrolyzed, the chylomicron remnants become 183 184 enriched with ApoE and ApoC2, the coenzyme for lipoprotein lipase, and are taken up by hepatocytes where remaining neutral lipids become hydrolyzed by cellular lipases¹⁵. VLDL are 185 assembled within hepatocytes and released into the blood stream to transport "endogenous" 186 TG, phospholipids and cholesterol. VLDL release TG and become IDL and then LDL with ApoE 187 188 determining their recycling to the liver. HDL particles remove cholesterol and fatty acids from cells and exchange neutral lipids with VLDL. ApoE is also present in a subfraction of HDL, 189 HDL_E, where it serves as a major factor determining their rapid uptake into the liver¹⁶. 190

191 There is strong evidence that in case of postprandial lipoprotein peaks or hyperlipoproteinemia 192 Kupffer cells contribute to hepatic clearance of circulating lipoprotein, either due to higher average lipoprotein size or due to oxidative modification¹⁷. Once lipoproteins have passed the 193 194 endothelial cell layer and reach the space of Disse, they are trapped by electrostatic 195 interactions with HSPG. There, hepatic lipase remodels the particles, giving them an optimal 196 size to interact with cell surface receptors and ApoE. The receptors that bind and take up 197 ApoE-containing remnant particles include the LDL receptor, the LDL-receptor related protein (LRP)-1 and HSPG¹⁸. Additionally, excess cholesterol is transported back to the liver in a 198 199 process known as reverse cholesterol transport mainly via high density lipoprotein (HDL). From 200 lipoproteins initially taken up by macrophages cholesterol can be effluxed to HDL and transported to the liver. Within macrophages, cholesterol esters of endocytosed lipoproteins 201 202 become hydrolysed by the endosomal acid lipase before free cholesterol is transported to the cell membrane via a Niemann-Pick C1 (NPC1)-dependent mechanism¹⁵. Finally, free 203 cholesterol is released from the macrophage and can bind extracellular lipid receptors such as 204 205 HDL enabling uptake into hepatocytes. Little is known about how much liver macrophages 206 contribute to reverse cholesterol transport to hepatocytes.

207 Since only humans or primates are productively infected with HBV and small animal models 208 are lacking, we developed a novel infection model system, in which human liver tissue is 209 perfused with labelled viral particles (VP). Using this ex vivo liver perfusion model we 210 unexpectedly found that HBV in association with lipoproteins was preferentially taken up by 211 liver macrophages into recycling endosomes and only thereafter accumulated in hepatocytes. Macrophages re-secreted HBV in association with free cholesterol derived from endocytosed 212 lipoproteins. Finally, HBV was taken up by hepatocytes along with macrophage-derived neutral 213 lipids supporting the conclusion that HBV can exploit the macrophage cholesterol transport as 214 215 one way to reach its host cell, the hepatocyte. We thus hypothesize that HBV uptake into 216 macrophages and subsequent trans-infection of hepatocytes represents an efficient strategy 217 for the pathogen to be sequestered in the liver, to avoid scavenger cells in the circulation or 218 spleen and to target hepatocytes.

219 **Results**

220 HBV primarily associates with liver macrophages prior to infecting hepatocytes

To identify the cell populations in the liver that in a physiological fashion are rapidly associated 221 with HBV, we established an ex vivo human liver tissue perfusion model with medium and 222 human serum (Fig 1A). Tissue viability was confirmed after 17-hour perfusion by scavenger 223 receptor-mediated uptake of ovalbumin into liver sinusoidal endothelial cells (Fig 1B). To 224 visualise early HBV infection events, we used purified viral particles (VP) comprising a mixture 225 226 of virions and filamentous subviral particles that express all three HBV envelope proteins (S, M and L), and labelled them with Alexa594 fluorochrome (VP₅₉₄) (Fig 1C). Such HBV VP₅₉₄ 227 were added to isolated liver macrophages and uptake of VP was detected and confirmed by 228 229 HBs staining using polyclonal antibodies. This demonstrated that purification and labelling 230 neither affected HBV envelope protein integrity nor particle uptake (Fig 1D). Co-localisation of VP₅₉₄ with HBsAg-specific staining confirmed specificity of VP₅₉₄-fluorescence labelling. 231 Staining of HBs after ex vivo perfusion of human liver tissue with HBV VP indicated uptake into 232 233 sinusoidal lining cells (Fig 1E). Antibody staining specificity was confirmed by absence of 234 staining of HBV-negative liver tissue (Fig 1F).

235 To study the physiological interaction of HBV with liver cells in the presence of serum 236 components the perfusion medium was supplemented with 50% human serum collected during a postprandial phase from a HBV-naïve and non-vaccinated individual. Demonstrating a 237 238 productive infection of hepatocytes by HBV in this experimental system, we detected HBV 239 cccDNA, the nuclear transcription template of HBV, at three days after the perfusion with HBV 240 particles, and secretion of newly synthesized HBV e antigen (HBeAg) (Fig 2A). Strikingly, after 241 a 45 min perfusion of the liver tissue with VP₅₉₄ in medium containing human serum, quantitative immunofluorescence analysis revealed that 97±2 % of CD68-positive liver 242 243 macrophages but not (0.9±1.3%) CD68-negative cells such as hepatocytes had taken up VP₅₉₄ 244 (Fig 2B-D). Similar results were obtained following perfusion of human liver tissue with 245 unlabelled HBV and detection of viral particles by immunofluorescence staining (Fig 2E).

Notably, HBV particles were also detected in liver macrophages in tissue sections from HBVinfected patients (**Fig 2F**). Moreover, a localization to macrophages was confirmed *in vivo* when we injected VP or HBV purified from human plasma into mice. Within 45 minutes or 1 h after intravenous injection, respectively, liver macrophages had already accumulated fluorescently labelled VP₅₉₄ and HBV DNA (**Fig 2G-I**). Taken together, these data indicate that HBV rapidly accumulates in macrophages but not hepatocytes thus raising the question whether HBV can escape lysosomal degradation in macrophages.

253

254 HBV localizes to recycling endosomes within macrophages

Since macrophages are specialised to clear pathogens from the circulation by lysosomal degradation, we next defined the intracellular location of internalized HBV particles in liver macrophages. To proof endocytosis of infectious HBV by human liver macrophages, isolated liver macrophages were incubated with purified HBV at 4°C or 37°C, respectively, and cellular viral rcDNA content was quantified. A significant increase of HBV rcDNA was detected associated with cells incubated at 37°C illustrating that liver macrophages do not only bind but actively take up infectious HBV (**Fig 3A**).

To determine the exact intracellular localization within liver macrophages, immunostainings 262 263 and confocal microscopy were performed. Already after one hour, VP₅₉₄ accumulated in an LAMP1-negative but Rab11-positive endosome, indicative of recycling endosomes but not 264 lysosomes (Fig 3B,C). Even after 17h, HBV particles remained localized in LAMP1-negative, 265 Rab11-positive recycling endosomes (Fig 3D,E). The localization of VP₅₉₄ to recycling 266 267 endosomes was confirmed using macrophages differentiated from the monocyte-macrophage cell line THP (Fig 4A,B,D,F). In striking contrast, recombinant subviral particles containing only 268 HBV S but lacking L and M proteins concentrated selectively in lysosomes (Fig 4C,E,G). 269

These data suggest that viral particles containing the L protein but not subviral particles without escape lysosomal trafficking and degradation within macrophages by targeting vesicles that are involved in recycling of endocytosed molecules to the cell surface.

273

274 HBV associates with lipoproteins in cell culture, in blood and in macrophages

275 We next addressed the question, which transport pathway within macrophages was hijacked by HBV to escape lysosomal degradation in perfused human liver tissue. Ultrastructural 276 analysis found HBV particles accumulated in liver macrophages (Fig 5A). These were virions 277 fulfilling all ultrastructural characteristics reported¹⁹ and, to a lesser extend, filamentous 278 279 subviral particles. No such particles were detected in non-perfused liver tissue. Within the macrophage, HBV was membrane-associated within intracellular, perinuclear compartments 280 or small vesicles. Interestingly, HBV-positive vesicles also contained lipoproteins, which 281 according to their size (70 nm) were most likely ultra-low density chylomicrons or VLDL (Fig 282 283 5A).

284 This prompted us to study whether HBV is associated with lipoproteins in sera from HBVinfected patients. Using density gradient ultracentrifugation we detected that HBV partially 285 floated in fractions of very low density. This was corroborated by DNA dot-blot analysis and 286 287 HBsAg-specific ELISA indicating an association with lipoproteins of ultra-low density (Fig **5B,C**). Interestingly, this HBV-positive, low-density fraction was not present anymore when 288 serum was filtrated through a 100 nm membrane. HBV-fractions of higher density, in contrast, 289 remained constant confirming an association with lipoproteins of very low density like 290 291 chylomicrons (Fig 5D). Furthermore, HBV started to sediment in a low-density fraction during sucrose gradient ultracentrifugation when incubated with human serum (Fig 5E). A mixed 292 ELISA using Apo-B and Apo-E capture antibodies (Fig 5F) was able to detect HBV indicating 293 that HBV associates to lipoproteins. Importantly, when we subjected subviral particles to mass 294 295 spectrometry analysis, we detected a 28-fold enrichment of ApoE (Fig 5G) associated to subviral particles. Finally, an association of HBV with lipoproteins was confirmed by electron 296

297 microscopy after immuno-gold staining (**Fig 5H**). Immuno-gold staining of HBV produced in 298 the hepatoma cell line HepAD38 that expresses endogenously ApoE detected ApoE locating 299 close to, yet distal of the virus particle which is in agreement with HBV association with an 300 ApoE-containing lipoprotein.

301

302 ApoE enhances HBV infection and HBV localizes to cellular compartments that 303 accumulate free cholesterol

304 We took advantage of a reporter virus that allows sensitive detection and quantification of HBV 305 infection by luciferase expression to address the question whether there is a functional role for 306 the HBV-lipoprotein association during infection (Fig 6A). Clearly, the addition of serum to HBV purified by CsCl gradient centrifugation was able to enhance HBV infection of hepatocytes (left 307 panel). This effect was diminished when the serum lacked ApoE, e.g., by using the serum of 308 ApoE-deficient mice (right panel). Moreover, the infection of differentiated HepaRG-cells with 309 310 HBV was significantly diminished when an LDL-receptor mediated uptake was inhibited using blocking antibodies during, but not after incubation of the cells with HBV (Fig 6B). These data 311 support the notion of an important function of HBV binding to lipoproteins for an early step of 312 313 HBV infection.

314 To study the intracellular transport of HBV particles and its relation to the intracellular recycling pathway of lipoprotein-derived free cholesterol, we incubated liver-derived macrophages with 315 chylomicrons containing fluorescent nitrobenzoxadiazole (NBD)-cholesterol and VP₅₉₄. Two 316 hours after endocytosis of the lipoproteins - when cholesterol esters were expected to be 317 318 hydrolyzed - perinuclear vesicles accumulating free cholesterol also contained HBV particles (Fig 6C). Strikingly, HBV co-incubated with human serum accumulated in Rab11-positive 319 recycling endosomes (Figs 3,4), which is consistent with publications reporting that free 320 cholesterol derived from ApoE-enriched TRL-remnants concentrates in recycling 321 endosomes^{20,21}. This indicates that HBV follows the recycling pathway of cholesterol derived 322 323 from chylomicrons in liver macrophages.

Recycling endosomes containing free cholesterol are intracellularly targeted by high-density 324 lipoprotein (HDL)-derived ApoA1²⁰. Since our stainings demonstrated that HBV localised in 325 326 liver macrophages in compartments concentrating TRL-derived free cholesterol (Fig 6C). 327 ApoA1-targeting provides a tool to track HBV particle transport in the macrophage. Indeed, 328 serum-derived HDL, when added to the cell culture medium, localized to vesicles containing HBV particles (Fig 6D), and HBV, when cultured in medium containing human serum, co-329 localised with ApoA1 (Fig 6E). In summary, these results demonstrate that HBV particles 330 accumulated in recycling endosomes together with lipoproteins enriched for cholesterol or 331 lipoprotein-derived cholesterol in peripheral as well as liver-derived macrophages. Our data 332 also stress the hypothesis that HBV employs the recycling pathway of lipoprotein-derived free 333 cholesterol in macrophages. 334

335

336 HBV is trans-cytosed through macrophages along free cholesterol transport pathways

337 To track the intracellular transport of HBV particles and lipoprotein-derived cholesterol in macrophages, we used human monocyte-derived macrophages because they exhibit lower 338 auto-fluorescence than liver macrophages and allow more sensitive detection of specific 339 340 fluorescence labels. HBV particles co-localized in perinuclear and cytosolic vesicles with filipin, which binds free cholesterol (Fig 7A). Treating macrophages with an inhibitor of cellular 341 cholesterol transport (U18666a) resulted in a perinuclear accumulation of cholesterol²². In 342 addition, transport of HBV particles from perinuclear compartments to the cell surface was 343 344 inhibited (Fig 7B,C) suggesting that HBV transport requires the free cholesterol transport pathway. Thus, HBV particles not only accumulated in subcellular compartments that 345 concentrate lipoprotein-derived free cholesterol but followed the directional intracellular 346 transport and transcytosis pathways of cholesterol. 347

Release of endosomal, lipoprotein-derived free cholesterol from macrophages is induced by high density lipoprotein (HDL) and HDL-derived ApoA1²⁰. Treating HBV inoculated macrophages with either HDL or ApoA1 increased the secretion of HBsAg and HBV-DNA (**Fig**

7D-F). When macrophages were incubated with HBV and [³H]-cholesterol-labelled chylomicrons, human serum induced their secretion and accordingly reduced their intracellular concentration (**Fig 7G**). These studies confirm that HBV is secreted from macrophages in analogy to cholesterol ready to enter the reverse cholesterol transport pathway to hepatocytes.

355

356 Redistribution of HBV particles from CD68+ macrophages to hepatocytes

Only hepatocytes support HBV replication and therefore are the final target cells of the virus 357 as neither macrophages nor dendritic cells support HBV replication²³. Thus, HBV particles 358 359 initially taken up by liver macrophages need to remain intact and be exocytosed for subsequent 360 infection of hepatocytes. To test this, human liver tissue was perfused for 45 min with VP₅₉₄ followed by a chase perfusion for 16h to allow for detection of redistribution of HBV particles. 361 While after 45 min HBV particles were confined to CD68+ liver macrophages (Fig 2B-E), after 362 the 16h chase, HBV localized within hepatocytes identified by HepPar1-staining (Fig 8A,B) 363 364 with approximately 34±9% of hepatocytes having internalized HBV. At this time point, 50±2% of CD68+ liver macrophages still stained positive for HBV, but with overall fewer particles per 365 cell (Fig 8C). 366

367 Cholesterol transport directly from macrophages to hepatocytes would provide a directional 368 pathway for HBV to target hepatocytes. To investigate whether this is an option, we visualized 369 intercellular lipid transport by staining neutral lipids including cholesterol esters and free 370 cholesterol with non-polar BODIPY 493/503. Hepatocytes showed a plasma membrane staining along with distinct intracellular, vesicular lipid droplets, while macrophages showed a 371 372 predominant intracellular staining pattern (Fig 8D,E). Of note, hepatocyte plasma membranes in close proximity to macrophages showed a markedly enhanced lipid staining, suggesting 373 membrane lipid exchange between the cells (Fig 8F). Additionally, macrophage membrane 374 protein CD68 was detected in hepatocyte cell membranes closely located to liver 375 376 macrophages, supporting the hypothesis of a direct intercellular membrane component exchanges (Fig 8G). In hepatocytes, HBV was exclusively detected at plasma membranes 377

with enhanced lipid staining (Fig 8D), or within lipid containing structures proceeding from the
plasma membrane into the interior of the hepatocyte (Fig 8E) supporting our model of reverse
transport of HBV from macrophages to hepatocytes.

381

382 HBV particles taken up by liver macrophages trans-infect hepatocytes

383 To characterize whether liver macrophages promote HBV-infection of hepatocytes in trans, we set up co-cultures of primary human liver macrophages and hepatocytes isolated from the 384 same donor. Liver macrophages were loaded with VP₅₉₄ and any unbound virus removed by 385 intensive washing before co-culturing with chloromethylfluorescein diacetate (CMFDA) 386 387 labelled hepatocytes. After an overnight co-culture, HBV was detected within CMFDA+ hepatocytes (Fig 9A). Of note, we observed filamentous intercellular connections (Fig 9B, 388 arrow), and an exchange of Dil-labeled membrane patches between macrophages and 389 hepatocytes (Fig 9C). 390

To evaluate whether macrophages can transfer infectious HBV to hepatocytes, liver 391 392 macrophages were incubated with HBV at either 4°C or 37°C for 6h, washed, trypsinized and incubated with primary human hepatocytes at 37°C for 12 days (Fig 9D). Only incubation at 393 37°C that allowed virus uptake into macrophages resulted in HBV infection of hepatocytes, 394 395 establishment of cccDNA (Fig 9E) and secretion of HBeAg and HBsAg (Fig 9F) while macrophage incubation at 4°C that did not allow for virus uptake did not result in HBV infection 396 397 of hepatocytes (Fig 9E,F). Importantly, liver macrophages themselves were not productively infected (Fig 9G). Trans-infection was blocked by the entry-inhibitor Bulevirtide and 398 399 neutralizing anti-HBs antibodies (Fig 9H) illustrating that trans-infection is also dependent on the bona fide HBV receptor. In addition, trans-infection was significantly reduced upon 400 U18666-mediated inhibition of cholesterol efflux from macrophages (Fig 9I). However, trans-401 infection of hepatocytes with HBV via liver macrophages was not more efficient than direct 402 infection of hepatocytes, suggesting trans-infection via liver macrophages is not necessarily a 403 preferential but rather an alternative infection route, at least in vitro (Fig 9J). Taken together, 404

- 405 our findings show that macrophages can internalize HBV, form intercellular membrane bridges
- 406 that could potentially promote cell-to-cell transmission of HBV and trans-infect hepatocytes via
- 407 a cholesterol efflux-dependent pathway.

408 **Discussion**

409 HBV infection relies on very efficient targeting of permissive hepatocytes since one single virus is able to establish infection in a chimpanzee¹. It remained unclear how HBV is able to reach 410 411 the liver without being phagocytosed in the circulation, how it bypasses liver scavenger cells 412 and how it is able to selectively target hepatocytes for infection. Here, we characterize these early steps of HBV uptake into the liver under physiological conditions using a novel liver 413 414 perfusion and infection model that allowed us to track HBV in liver tissue. Interestingly, HBV 415 was rapidly taken up into liver macrophages and only at a later time point detected in hepatocytes. We found that HBV associates with human serum lipoproteins and ApoE. Within 416 macrophages, HBV localized to the same endosomal compartments as lipoproteins before 417 being released along the cholesterol efflux pathway. HBV released after trans-infection of 418 419 macrophages was able to infect hepatocytes. Since lipoprotein and reverse cholesterol transport to the liver is an efficient physiological process, we hypothesise that HBV exploits 420 this pathway to reach the liver and infect hepatocytes. 421

422 Accordingly, we propose the following model for HBV host cell targeting. HBV - after 423 association with ApoE-rich lipoproteins - attaches to liver-specific HSPG that protrude from the Space of Disse across endothelial fenestration into the liver sinus²⁴. Subsequently, HBV may 424 be taken up directly into hepatocytes or first into liver macrophages. The ratio of direct host 425 cell targeting vs. trans-infection is likely to be determined by individual lipidemic¹⁷ and/or 426 microstructural liver sinus²⁵ conditions. HBV sequestered by liver macrophages, hijacks the 427 intracellular lipoprotein metabolism and is re-secreted along the free cholesterol-recycling 428 pathway. Free cholesterol and HBV are then delivered from the macrophages via intercellular 429 membrane bridges to neighbouring hepatocyte plasma membranes where interaction with the 430 431 HBV receptor NTCP can prime a productive infection. Thus, the hepatotropism of HBV as well its ability to survive within the circulation may depend on the utilization of cellular lipid transport 432 pathways that are hepatocyte-directed. 433

The bile-acid transporter peptide NTCP has recently been identified as a HBV receptor that is 434 exclusively expressed on hepatocytes². How HBV gains access to hepatocellular NTCP in vivo 435 is not understood since endothelial cells lining the sinusoids restrict passive diffusion of 436 particles >12 nm in diameter²⁵. Since HBV is an enveloped virus with a diameter of 42 nm, it 437 seems unlikely that HBV can passively diffuse through this layer of sinusoidal cells with the 438 439 efficiency needed to promote the high in vivo particle infectivity that has been reported¹. 440 Moreover, one has to consider the scavenging activity of LSECs and liver macrophages that 441 could easily trap and lyse HBV. A directed transport exploiting a transcytosis pathway through 442 macrophages as we have observed would be able to overcome these hurdles. Preferential uptake of HBV by liver macrophages - as we observed in vivo in mice - may result from initial 443 binding to liver specific HSPG^{3,4} extending into the liver sinus. Binding to these HSPG has 444 been observed e.g. for plasmodium sporozoites²⁴. 445

Since HBV does not require distinct glycosaminoglycans found in the liver to confer hepatocyte 446 specificity³, the association with serum components like lipoprotein remnants may increase 447 targeting to hepatic glycosaminoglycans and other lipoprotein receptors. This reasoning is 448 449 supported by our and others recent findings that liver uptake is significantly reduced in ApoEdeficient mice and that HBV infection is inhibited by ApoE-specific antibodies in vitro, 450 respectively^{13,14}, as well as by reports that HBV binds to ApoH and lipoprotein lipase^{26,27}, both 451 452 surface components of lipoproteins. In our study we demonstrate that HBV associates with 453 lipoproteins in patients' serum and when release from producer cells, and that blocking LDL-454 receptor function on hepatocytes markedly reduces productive infection. Importantly, efficient hepatocyte infection relied on the presence of ApoE supporting the crucial role of an 455 association of HBV to ApoE-containing lipoproteins. 456

Electron microscopy analysis after immunogold staining strongly supported the association of
HBV with ApoE-containing lipoproteins. Interestingly, ApoE was detected distal of the virus
particle in accordance with an association of a lipid particle smaller than 100 nm in diameter,
presumably an ApoE-containing HDL or a small VLDL/LDL. An exact quantification of the HBV-

461 lipoprotein association, however, is difficult since the purification of HBV requires 462 ultracentrifugation that is known to dissociate proteins from lipoproteins²⁸. As the virus-463 lipoprotein association rather is of lower affinity, virions may have dissociated during 464 purification resulting in an underestimation of the association of HBV with lipoproteins of low 465 density in our experiments.

466 In addition to mediating liver-tropism, lipoprotein embedded cholesterol may facilitate HBV recycling within macrophages as described for lipoprotein-associated proteins like ApoC, ApoE 467 and lipoprotein lipase²¹. Lipoproteins bind to LDL-receptors on hepatocytes via ApoE, that has 468 allelic variants ApoE1 to 4. ApoE3 more potently binds the LDL-receptor and induces cellular 469 cholesterol recycling than its allelic variants²⁹. Interestingly, the ApoE3 allele is 470 overrepresented in HBV-infected patients and subjects with an ApoE3 allele have a lower rate 471 of spontaneous HBsAg clearance^{30,31}. Thus, clinical observations support an important role of 472 473 lipoprotein metabolism and transport to the liver in early HBV infection. Finally, association of 474 HBV infection with lipoprotein-metabolism is further supported by inhibition of an early infection step by lipase inhibitor Orlistat¹³. 475

The contribution of macrophages to reverse cholesterol transport represents a physiological 476 477 pathway, by which cholesterol derived from circulating lipoproteins is endocytosed into recycling endosomes in macrophages, effluxed to lipid acceptors and delivered to hepatocytes, 478 especially under hyperlipidemic conditions and in the postprandial situation^{15,17}. Lipids effluxed 479 from liver macrophages are incorporated into hepatocytes in vivo¹⁷. The N-terminal acyl 480 residue of the HBV L protein may mediate transport along the free cholesterol transport 481 pathway as described for influenza hemagglutinin³² and other acylated proteins including 482 glycosylphosphatidylinositol anchored proteins. 483

Liver resident macrophages are located in close proximity to hepatocytes that are specialised in cholesterol uptake. Intercellular membrane bridges between neighbouring donor and acceptor cells have been suggested to support lipid transport³³. We observed intercellular membrane bridges between liver resident macrophages or Kupffer cells and hepatocytes and

the transfer of lipids and membrane proteins from Kupffer cell to hepatocyte membranes suggest a direct exchange of membrane components between neighbouring cells. This principle is exploited by prions, which - as HBV - recycle along the free cholesterol pathway to the plasma membrane and are directly transferred to neighbouring cells via membrane bridges^{34,35}. Thus, routing along the recycling cholesterol transport pathway in liver macrophages and transcellular delivery to hepatocytes through intercellular membrane bridges appear to act in concert to facilitate hepatocyte-targeting by HBV.

495 In conclusion, it seems that as for other viruses, specific host cell targeting by HBV does not 496 only result from a particular virus-receptor interaction on the target cell. Our results propose 497 that HBV in vivo associates with lipoproteins, may take advantage of their liver targeting and 498 is able to hijack the cholesterol transport pathway through macrophages. These pathways 499 have been evolutionary optimized to deliver their cargo from distant sites to the liver and may 500 explain the highly efficient liver targeting by HBV. They are suited to support the deposition of HBV in the persinusoidal Space of Disse from where HBV can bind its receptor on hepatocytes 501 or even be directly transport to hepatocytes by the establishment of membrane bridges. 502

503

504 Materials and Methods

All authors had access to the study data and had reviewed and approved the final manuscript.

506 For additional details on materials, providers and procedures see Supplemental Information.

507

508 *Ex vivo* human liver perfusion

509 HBV viral particles were purified by sequential sucrose and CsCl gradient sedimentations and 510 fluorescence labelled with Alexa Fluor 594® (VP₅₉₄). Human liver tissue samples and 511 annotated data were obtained and experimental procedures were performed within the 512 framework of the non-profit foundation HTCR, including the informed patient's consent. 513 Surgical human liver biopsies (10 to 20 g) consisting of healthy tissue obtained during 514 metastasis resection were perfused within 2 hours with medium containing HBV, VP₅₉₄ and

human serum as indicated via portal vein branches at 37°C. To potentially increase HBV-TRLassociations, postprandial but not preprandial serum was used. For longer perfusions, 12%
erythrocytes were added and oxygen was supplied.

518 Virus uptake into liver cells

519 Primary human hepatocytes and liver macrophages were isolated by two-step collagenase 520 perfusion followed by differential centrifugation and adherence steps and maintained as 521 described³⁶. Human serum negative for anti-HBs antibodies and monocytes for differentiation 522 into macrophages were obtained from healthy volunteers.

523 Liver macrophages were incubated with HBV at a multiplicity of infection (MOI) of 100 enveloped, DNA-containing HBV particles, washed five times, trypsinized at 37°C for 15 524 minutes, centrifugated for 5 min at 300 g, adhered to the culture surface for 1h, three times 525 washed and subsequently hepatocytes were seeded on top. Re-secretion and (trans-)infection 526 were monitored by determining HBsAg, HBeAg and HBV-DNA in cell culture supernatant. HBV 527 cccDNA was determined in infected hepatocyte lysates by guantitative RT-PCR²³. HBV RNA 528 was isolated using the Monarch Total RNA Miniprep Kit according to the manufacturer's 529 protocol but with 1h of DNAse digestion. cDNA was synthesized with LunaScript RT SuperMix 530 Kit (with a denaturation step of the RNA for 5 min 95°C, incubation on ice, 50 min 50°C, 5 min 531 95°C) (both New England Biolabs, Ipswich, MA, USA). For qPCR, primers/probes from Life 532 Technologies (Thermo Fisher, Frankfurt, Germany) were used. 533

To analyse the functional contribution of lipoproteins, recombinant (r)HBV expressing 534 NanoLuc-Luciferase (rHBV-Luc) was produced as previously described³⁷ that allows for a 535 536 sensitive and quantitative infection. To remove supernatant- and particle-associated proteins, recombinant rHBV-Luc was highly purified via heparin-affinity chromatography and 537 subsequent sucrose- and CsCl-gradient ultracentrifugation. rHBV-Luc particles were 538 concentrated and buffer exchanged in PBS, and cells were infected with the highly purified 539 rHBV in the presence or absence of 10% FCS, or serum obtained from CH57B6/N wild-type 540 or ApoE-knockout mice. To determine infection efficacy, 10 µL cell culture supernatant were 541

mixed with 100 µL PBS containing 0.1% Tween 20 and 1 µM Coelenterazine N as described³⁸.
Luminescence was detected using a Tecan Infinite 200 reader (Tecan Group Männedorf,
Switzerland).

545 Isolation of mouse hepatocytes and liver macrophages

Mouse livers were perfused by a standard two-step collagenase perfusion through the portal vein *in situ* before the liver was collected and the tissue was homogenized and passed through a cell strainer. The cell suspension was incubated with magnetic CD11b-specific MicroBeads and loaded onto a MACS column (both Miltenyi Biotec, Bergisch Gladbach, Germany) to collect macrophages according to the manufactures protocol. The remaining cell solution was centrifuged twice for 5 minutes at 50 g without break to collect hepatocytes.

552 **Re-secretion from macrophages**

THP macrophages were differentiated with 70 nM phorbol-12-myristate-13-acetate and incubated with 1×10^8 HBV virions / ml (final concentration) for 3 hours and subsequently without HBV, but adding 10% human serum, 100 or 200 µg/ml HDL as indicated. To determine cholesterol secretion, 1 µg/ml [3H]-cholesterol-chylomicrons were added to the HBV incubation, and heparin was added to the washing. [3H]-cholesterol was quantified in supernatant and cell lysates by liquid scintillation counting.

559 Electron microscopy of liver tissue

10 µm cryosections of liver tissue or PFA-fixed cells were permeabilized with PBS / 0.5% 560 saponin and stained with appropriate primary and indicated secondary antibodies. To stain 561 562 neutral lipids BODIPY493/503 (1/250), to stain free cholesterol 50 µg/ml filipin was used. All images were acquired on an Olympus FluoView 1000-confocal laser-scanning microscope. 563 564 For transmission electron microscopy, liver tissue was fixed with 2.5% glutaraldehyde in 0.1 mol/l cacodylate, post-fixed with 1% OsO4 and stained with uranyl acetate followed by lead 565 citrate. Ultra-thin section were analyzed on a Zeiss EM 10 CR electron microscope (Zeiss, 566 Oberkochen, Germany). 567

Immuno-gold staining and electron microscopy of HBV virions 568

Sucrose fractions containing HepAD38 cell-derived HBV virions were diluted with TN buffer 569 (20 mM Tris-HCL pH 7.4 and 140 mM NaCl) and fixed with 2% PFA for 4 hours at 40°C. 570 Residual sucrose and PFA were removed by using Amicon Ultra (30k) centrifugal filter units 571 by diluting and washing concentrated samples with TN buffer. Freshly glow-discharged 572 573 carbon- and pioloform-coated 300-mesh copper grids (Science Services GmbH, Munich, Germany) were floated on top of 10 µl of different dilutions of sucrose-free HBV particles for 5 574 minutes. After removal of the sample by soaking into Whatman paper, the grid was briefly 575 576 washed by floating on a droplet of 3% uranylacetate (UA) solution, followed by another floating on a fresh 3% UA droplet for 2 minutes. The stain was removed by soaking into Whatman 577 paper and the grid was air-dried at room temperature before staining and imaging with a JEOL 578 JEM-1400 transmission electron microscope (Jeol GmbH, Freising, Germany). 579

Quality of the HBV virion-containing samples was assessed by TEM analysis of negatively 580 stained samples. Immuno-gold labeling that was performed as described elsewhere³⁹. In brief, 581 samples absorbed onto glow-discharged grids were washed with H₂O, incubated for 20 582 minutes in blocking buffer (0.8% BSA, 0.1% fish skin gelatin, 50 mM glycine in PBS) and 583 584 incubated with primary antibodies for 20 minutes in blocking buffer, followed by 5-times washing of the grids with PBS before incubation of the grids with Protein A-10 nm gold 585 conjugate (Cell Microscopy Core, NL) in blocking solution for 20 minutes. The antibodies used 586 for immuno-gold labeling were anti-ApoE (Sigma-Aldrich - AB947), anti-HBsAg (Humabs 587 588 Biomed – HBC34) and goat-IgG isotype control (Santa Cruz – Sc2028). Thereafter, the grids were washed again with PBS and fixed with 1% glutaraldehyde in PBS for 5 minutes. 589

590

Mass spectrometry of purified HBV subviral particle fractions

Subviral particles were produced in HepG2 cells stably transfected with a plasmid encoding 591 HBV genome 2415-1839 expressing all three HBV surface proteins (HepG2-LMS). Particles 592 were purified as previously described via heparin-affinity chromatography and sucrose 593 gradient ultracentrifugation⁴³. Fractions containing the subviral particles were collected, 594

concentrated and buffer exchanged to PBS using VivaSpin 6 filter units (100 000 MWCO, 595 596 Sartorius) and analyzed via liquid chromatography/mass spectrometry (LC/MS) using an Orbitrap Eclipse Tribrid mass spectrometer (Thermo Fisher). Supernatant of HepG2 cells not 597 598 expressing HBV proteins was purified as control. A HepG2-LMS and HepG2 control sample were denatured with urea lysis buffer (8 M Urea, 50 mM Tris-HCl pH 7.5) followed by reduction 599 with 10 mM DTT for 45 min at 30°C and alkylation of cysteines with 55 mM CAA for 30 min at 600 room temperature. Samples were diluted 1:5 with digestion buffer (Tris-HCl pH 8.5, 2 mM 601 602 CaCl2) and digested with trypsin at 1:50 enzyme-to-protein ratio at 37°C overnight. Samples 603 were acidified with 1% formic acid (FA) followed by desalting on self-packed StageTips. Peptides were eluted with 50% ACN, 0.1 % FA and dried down prior to LC-MS/MS analysis. 604 LC-MS/MS measurements were performed on a Dionex Ultimate 3000 RSLCnano system 605 606 coupled to an Orbitrap Eclipse mass spectrometer (Thermofisher Scientific, Bremen), Peptides were reconstituted in 0.1% FA and measured in data dependent acquisition mode with a 50 607 608 min linear LC gradient. Peptide and protein identification and quantification was performed with MaxQuant software (v. 1.6.3.3) with standard settings unless otherwise described⁴⁴. Raw files 609 610 were searched against the human and bovine reference proteome (UP000005640, download 01/2021; UP000009136, download 04/2022), a customized HBV sequence fasta file and 611 612 common contaminants. Carbamidomethylated cysteine was set as fixed modification and 613 oxidation of methionine, and N-terminal protein acetylation as variable modifications. Trypsin/P was specified as the proteolytic enzyme with up to two missed cleavage sites allowed. Results 614 were adjusted to 1% peptide spectrum match and 1% protein false discovery rate (FDR). 615 Displayed protein abundances are based on log2 transformed median centered iBAQ 616 intensities. 617

618 Statistical analysis

Data are given as mean ± SD unless otherwise indicated. Statistical analysis was performed
using unpaired student's t-test or by Two-Way ANOVA when more than two groups were
compared.

622 Confirmatory statement

All authors had access to the study data. Additionally, the final manuscript has been reviewedand approved by all authors.

625

626 Acknowledgements

The authors thank Luise Jennen, Lilianna Schyschka and Raindy Tedjokusumo for excellent technical support, Jörg Kleeff and Sonja Gillen for support with the ethic's application and patient information, and Jane McKeating for critically reading the manuscript. We are grateful to the Heidelberg University electron microscopy core facility, headed by Charlotta Funaya. We acknowledge the support of the non-profit foundation HTCR, which holds human tissue on trust, making it broadly available for research on an ethical and legal basis.

633

634 **References**

Asabe, S. et al. The Size of the Viral Inoculum Contributes to the Outcome of Hepatitis B Virus 635 1. Infection. J. Virol. (2009). doi:10.1128/jvi.00867-09 636 637 2. Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012, (2012). 638 3. Leistner, C. M., Gruen-Bernhard, S. & Glebe, D. Role of glycosaminoglycans for binding and 639 infection of hepatitis B virus. Cell. Microbiol. 10, 122-133 (2008). 640 4. Schulze, A., Gripon, P. & Urban, S. Hepatitis B virus infection initiates with a large surface 641 642 protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46, 1759–1768 643 (2007). 5. Protzer, U., Maini, M. K. & Knolle, P. A. Living in the liver: Hepatic infections. Nature Reviews 644 645 Immunology (2012). doi:10.1038/nri3169 Gardner, J. P. et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. 646 6. 647 Proc. Natl. Acad. Sci. U. S. A. (2003). doi:10.1073/pnas.0831128100 648 7. Lai, W. K. et al. Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: A 649 role for capturing hepatitis C virus particles. Am. J. Pathol. (2006).

650		doi:10.2353/ajpath.2006.051191
651 652	8.	Cormier, E. G. <i>et al.</i> L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. <i>Proc. Natl. Acad. Sci. U. S. A.</i> (2004). doi:10.1073/pnas.0405695101
653 654	9.	Rowe, I. A. <i>et al.</i> Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. <i>Hepatology</i> (2014). doi:10.1002/hep.26571
655 656 657	10.	Breiner, K. M., Schaller, H. & Knolle, P. A. Endothelial cell-mediated uptake of a hepatitis B virus: A new concept of liver targeting of hepatotropic microorganisms. <i>Hepatology</i> (2001). doi:10.1053/jhep.2001.27810
658 659	11.	Frevert, U. <i>et al.</i> Intravital observation of plasmodium berghei sporozoite infection of the liver. <i>PLoS Biol.</i> (2005). doi:10.1371/journal.pbio.0030192
660 661	12.	Tavares, J. <i>et al.</i> Role of host cell traversal by the malaria sporozoite during liver infection. <i>J. Exp. Med.</i> (2013). doi:10.1084/jem.20121130
662 663	13.	Esser, K. <i>et al.</i> Lipase inhibitor orlistat prevents hepatitis B virus infection by targeting an early step in the virus life cycle. <i>Antiviral Res.</i> (2018). doi:10.1016/j.antiviral.2018.01.001
664 665	14.	Qiao, L. & Luo, G. G. Human apolipoprotein E promotes hepatitis B virus infection and production. <i>PLOS Pathog.</i> (2019). doi:10.1371/journal.ppat.1007874
666 667	15.	Ikonen, E. Cellular cholesterol trafficking and compartmentalization. <i>Nat. Rev. Mol. Cell Biol.</i> 9 , 125–138 (2008).
668 669	16.	Richard, B. M. & Pittman, R. C. ROLE OF HDL1 IN CHOLESTERYL ESTER UPTAKE IN RATS. <i>J. Lipid Res.</i> 34 , 571–579 (1993).
670 671 672 673	17.	van DIJK, M. C. M., ZIERE, G. J. & van BERKEL, T. J. C. Characterization of the chylomicron- remnant-recognition sites on parenchymal and Kupffer cells of rat liver Selective inhibition of parenchymal cell recognition by lactoferrin. <i>Eur. J. Biochem.</i> (1992). doi:10.1111/j.1432- 1033.1992.tb16842.x
674 675	18.	Mahley, R. W. & Ji, Z. S. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. <i>Journal of Lipid Research</i> (1999).
676 677 678	19.	Roingeard, P. & Sureau, C. Ultrastructural analysis of hepatitis B virus in HepG2-transfected cells with special emphasis on subviral filament morphogenesis. <i>Hepatology</i> (1998). doi:10.1002/hep.510280431
679 680	20.	Heeren, J. <i>et al.</i> Recycling of apoprotein E is associated with cholesterol efflux and high density lipoprotein internalization. <i>J. Biol. Chem.</i> (2003). doi:10.1074/jbc.M209006200
681 682 683	21.	Heeren, J., Grewal, T., Jäckle, S. & Beisiegel, U. Recycling of Apolipoprotein E and Lipoprotein Lipase through Endosomal Compartments in Vivo. <i>J. Biol. Chem.</i> (2001). doi:10.1074/jbc.M107461200

684 22. Higgins, M. E., Davies, J. P., Chen, F. W. & Ioannou, Y. A. Niemann-pick C1 is a late 685 endosome-resident protein that transiently associates with lysosomes and the trans-Golgi 686 network. Mol. Genet. Metab. (1999). doi:10.1006/mgme.1999.2882 687 23. Untergasser, A. et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 43, 539-547 (2006). 688 689 24. Pradel, G., Garapaty, S. & Frevert, U. Proteoglycans mediate malaria sporozoite targeting to 690 the liver. Mol. Microbiol. (2002). doi:10.1046/j.1365-2958.2002.03057.x 691 25. Kempka, G. & Kolb-Bachofen, V. Binding, uptake, and transcytosis of ligands for mannose-692 specific receptors in rat liver: An electron microscopic study. Exp. Cell Res. (1988). 693 doi:10.1016/0014-4827(88)90118-8 694 26. Stefas, I. et al. Hepatitis B virus Dane particles bind to human plasma apolipoprotein H. Hepatology (2001). doi:10.1053/jhep.2001.20531 695 696 27. Deng, Q. et al. Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site. J. Virol. 81, 4244-54 (2007). 697 698 28. Heeren, J., Niemeier, A., Merkel, M. & Beisiegel, U. Endothelial-derived lipoprotein lipase is 699 bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo. 700 J. Mol. Med. (2002). doi:10.1007/s00109-002-0351-5 701 Schneider, W. J., Kovanen, P. T. & Brown, M. S. Familial dysbetalipoproteinemia. Abormal 29. 702 binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and 703 membranes from liver and adrenal of rats, rabbits, and cows. Journal of Clinical Investigation **68**, 1075–1085 (1981). 704 705 30. Toniutto, P. et al. Genetic polymorphism at the apolipoprotein E locus affects the outcome of 706 chronic hepatitis B. J. Med. Virol. 82, 224-231 (2010). 707 31. Ahn, S. J. et al. Association between apolipoprotein E genotype, chronic liver disease, and 708 hepatitis B virus. Clin. Mol. Hepatol. 18, 295-301 (2012). 709 32. Melkonian, K. A., Ostermeyer, A. G., Chen, J. Z., Roth, M. G. & Brown, D. A. Role of lipid 710 modifications in targeting proteins to detergent-resistant membrane rafts. Many raft proteins 711 are acylated, while few are prenylated. J. Biol. Chem. (1999). doi:10.1074/jbc.274.6.3910 712 33. Rustom, A., Saffrich, R., Markovic, I., Walther, P. & Gerdes, H. H. Nanotubular Highways for 713 Intercellular Organelle Transport. Science (80-.). (2004). doi:10.1126/science.1093133 714 34. Gilch, S., Bach, C., Lutzny, G., Vorberg, I. & Schätzl, H. M. Inhibition of cholesterol recycling impairs cellular PrPSc propagation. Cell. Mol. Life Sci. (2009). doi:10.1007/s00018-009-0158-4 715 35. Gousset, K. et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat. Cell Biol. 716 717 (2009). doi:10.1038/ncb1841

- 36. Ebert, G. *et al.* 5' triphosphorylated small interfering RNAs control replication of hepatitis B
 virus and induce an interferon response in human liver cells and mice. *Gastroenterology* 141,
 (2011).
- 37. Wing, P. A. C. *et al.* Hypoxia inducible factors regulate hepatitis B virus replication by activating
 the basal core promoter. *J. Hepatol.* **75**, 64–73 (2021).
- Ryu, J. *et al.* Rapid, accurate mapping of transgene integration in viable rhesus macaque
 embryos using enhanced-specificity tagmentation-assisted PCR. *Mol. Ther. Methods Clin. Dev.* 24, 241–254 (2022).
- 39. Pham, M. *et al.* Endosomal egress and intercellular transmission of hepatic ApoE-containing
 lipoproteins and its exploitation by the hepatitis C virus. Preprint from bioRxiv (2022).
- 40. Wettengel, J. M. *et al.* Rapid and Robust Continuous Purification of High-Titer Hepatitis B Virus
 for In Vitro and In Vivo Applications. *Viruses* **13**, (2021).

731 Figure Legends

732

733 Fig 1: Establishment of an *ex vivo* perfusion model of human liver tissue.

734 (A) Schematic depiction of the ex vivo perfusion system. Inside a cell culture incubator, liver 735 tissue was kept in a sterile container filled with medium containing human serum. Using a perfusion pump, the tissue piece was continuously perfused via branches of the portal vein. 736 737 (B) Liver tissue was perfused for 17 h with 50% human serum containing medium. For 30 min, 20 µg/ml Alexa Fluor®647-labelled ovalbumin was added to assess receptor mediated 738 endocytosis and confirm intact liver cell function. Fixed liver tissue sections were analysed by 739 740 confocal laser scanning microscopy. (C) Purified HBV particles were subjected to 10% SDS-PAGE before (left) or after Alexa594 fluorochrome-labeling (VP594, right). Gels were either 741 silver stained (left) or investigated for fluorescence ($\lambda ex./\lambda em. = 365/602$, right). Arrows 742 743 indicate large (L), middle (M) and small (S) envelop proteins at expected molecular weight 744 (kDa). (D) Isolated liver macrophages were incubated with medium containing VP594 for 1h 745 before cells were washed and fixed. Cells were stained with HBsAg-specific antibodies and 746 Alexa488-labelled secondary antibodies. Merged pictures show VP₅₉₄ in red and HBsAg in green with arrows pointing at co-localising VP₅₉₄ with HBsAg-specific staining. (E) After 45 min 747 perfusion with unlabelled HBV VP liver tissue sections were stained with polyclonal rabbit anti-748 749 HBs and fluorescent secondary antibodies (left panel). As control, perfused tissue was stained 750 with rabbit control serum (right panel) to confirm specificity of HBsAg-detection. (F) Liver tissue of an HCV-infected, but HBV-negative patient was fixed and stained with HBsAg- and CD68-751 752 specific primary and fluorescent secondary antibodies showing no HBsAg-detection in HBV-753 negative tissue. Scale bar is 10 µm in (B, D-F).

754

755 Fig 2: Uptake of HBV particles by liver macrophages in *in vivo* perfused human livers.

(A) Human liver tissue pieces were perfused at 37°C with medium containing 5x10⁹ HBV 756 virions/ml and 50% human serum for 17h and subsequently with medium only for 58h. Before 757 and at the end of perfusion, tissue sections were lysed and DNA was extracted. HBV cccDNA 758 content was determined by a selective real time PCR and is given relative to cellular PRNP 759 gene expression, each dot represents a randomly taken liver tissue sample (left panel); 760 perfusate was analysed for HBeAg content by ELISA (mean \pm SD of OD₄₅₀, duplicates), a 761 762 separate piece of liver tissue from the same donor perfused with HBV-negative medium served as negative control (right panel). (B-F) Human liver tissue pieces were perfused at 37°C for 45 763 min with medium containing 50% human serum and 10¹⁰ VP₅₉₄/ml (shown in red), and fixed 764 tissue sections were stained for macrophage marker CD68 (shown in green). (B) Differential 765 interference contrast (DIC) showing liver sinusoids with hepatocytes next to CD68-stained liver 766 macrophages. (C) Quantification of CD68⁺ or CD68⁻, HBV+ cells. Analysis of ten random vision 767 fields (200-fold magnification; mean values ± SD). (D) XY- and Z-axis projection at higher 768 769 magnification to visualize intracellular localization of VP₅₉₄ in macrophages (y-z), cell nucleus 770 stained with DAPI. (E) Immunofluorescence staining for CD68 and HBsAg in fixed tissue 771 sections perfused with non-labelled HBV. (F) Immunostaining of liver tissue from a chronically infected HBV patient for HBsAg (shown in red) and CD68 (shown in green). Lower row shows 772 the boxed area enlarged. (G-I) CH57BI/6 mice were intravenously injected through the tail vein 773 with (G,H) 2x10¹¹ FITC (VP_{FITC}) labelled VP or (I) 1x10⁹ virions purified from HBV-positive 774 plasma after filtration through a 100 nm pore size filter. (G) After 45 min mouse livers were 775 fixed, liver sections were stained with macrophage maker F4/80 and analysed by confocal 776

⁷⁷⁷ laser-scanning microscopy. Y-axis (y-z) and z-axis projections (x-z) are shown. Merged ⁷⁷⁸ pictures show VP_{FITC} in green. (**H**) Numbers of VP_{FITC}-positive, F4/80+/– cells (ten randomly ⁷⁷⁹ selected vision fields at 200-fold magnification). (**I**) 1h after injection, liver macrophages and ⁷⁸⁰ hepatocytes were isolated. Cellular DNA was prepared and analysed by quantitative RT-PCR ⁷⁸¹ for HBV-DNA relative to NID2 as house-keeping gene. Values are mean ± SEM of two ⁷⁸² independent experiments, with triplicates analyzed per experiment. **p=0,0012. All scale bars ⁷⁸³ are 10 µm.

784

785 **Fig 3: HBV cellular localisation in human primary liver macrophages.**

- (A) Primary human liver macrophages were incubated with purified HBV for 4 h either at 37°C 786 or 4°C, and after washing were lysed and HBV DNA was quantified by qPCR. Means±SD of 787 one representative experiment with three independent replicates in each group are shown. 788 *p<0.5. (B-E) Liver macrophages were incubated with VP₅₉₄ in medium containing 10% human 789 serum for 1h, thoroughly washed and either immediately fixed (B,C) or further cultivated for 790 16h in absence of HBV to follow intracellular transport of HBV (D, E). After fixation cells were 791 792 stained for LAMP1 (**B** and **D**) or Rab11 (**C** and **E**). Merged pictures show VP₅₉₄ in red, CD 68, 793 LAMP1, and Rab11 staining in green, and nuclear staining with DAPI in blue. Representative
- images of single liver macrophages are shown, scale bars are 10 $\mu m.$
- 795

796 Fig 4: Differential localization of HBV and recombinant HBsAg in THP macrophages.

- THP macrophages were incubated with medium containing fluorochrome-labelled HBV (VP₅₉₄; 797 A, B, D, F) or recombinant HBsAg (HBsAg₅₉₄; C, E, G) for 1h. Cells were either directly fixed 798 after washing (A) or further cultivated without HBV for 16h (B, C) and stained for Rab11. (D-799 G) Cells were either directly fixed after washing (D, E) or after further cultivation without HBV 800 or HBsAg for 16 h (F, G) and stained for LAMP1. Merged pictures show VP₅₉₄ and HBsAg₅₉₄ 801 in red, Rab11 and LAMP1 in green, and nuclear staining with DAPI in blue. Scale bar 10 µm. 802 803 Co-localization determined in three randomly selected vision fields of each group was analyzed 804 using Manders' correlation method. Mred (fraction of red overlapping with green) was calculated using JACoP plugin of ImageJ. The means±SD of four random views of one 805 representative experiment are shown as bar graphs next to the respective image. ***p<0.001, 806 ****p<0.0001. 807
- 808

809 Fig 5: Association of HBV with lipoproteins. (A) Human liver tissue was perfused for 45 min at 37°C with medium containing human serum and HBV (perfused tissue) or directly fixed 810 without perfusion with HBV (non-perfused tissue) as negative control. Transmission electron 811 microscopy shows liver macrophages (KC) next to a hepatocyte (Hep) in HBV perfused and 812 non-perfused liver tissue (left panels), areas marked in red are shown at higher magnification 813 (right panels). Exemplary sections are shown, demonstrating co-localization of triglyceride-rich 814 815 lipoprotein (TRL) and HBV particles in perfused livers (white arrows) and an example of lipoproteins in a non-perfused liver (dark arrows). Scale bars indicate 1µm (left panels) and 816 817 100nm (right panels) LD: lipid droplets; Ery: erythrocytes. (B-D) The plasma sample of an HBV infected patient was separated by sucrose density gradient ultracentrifugation either directly 818 (B,C) or after filtration through a membrane of 100 nm pore size (D). Indicated fractions (Fr.) 819 were analysed for HBV-DNA by dot blot-analysis (B,D) and for HBsAg content by ELISA (C). 820 (B,D) Volumes dotted are indicated above, HBV-DNA-content and density of each fraction are 821 822 given below the dot blots. (C) HBsAg content of ultra-low density fractions 25 and 26 from non823 filtered plasma is shown. Fraction 26 proved positive for HBV-DNA and HBsAg. (E) HBV virions contained in high density fraction 3 were further purified by CsCI-density centrifugation. After 824 buffer-exchange to PBS, HBV virions were incubated for 30 minutes at 37°C with or without 825 human serum (10% v/v; anti-HBs-negative) and subjected to sucrose density gradient 826 centrifugation. HBV-DNA was detected in fractions of low density (indicated by arrows) after 827 incubation with serum (lower row). (F) Mixed ELISA of human plasma containing HBV (left 828 panel: 3x10⁵ - 3x10⁷ virions; right panel: 3x10⁵ virions) using anti-ApoB (left panel) or anti-829 ApoE capture (right panel) and anti-HBs detection antibodies. (G) Proteins detected by mass 830 spectrometry of supernatant-purified HBV subviral particles (HepG2-LMS) or control fractions 831 832 show association of ApoE and HBsAg (red cross). (H) HBV particles purified by sucrose density ultracentrifugation from stable producer cells HepAD38 were analysed by immune 833 834 electron microscopy with gold-labelled anti-ApoE- (upper panel) and anti-HBsAg-specific antibodies (picture below). Pictures show distant localisation of ApoE and proximal localisation 835 836 of HBsAg. Scale bars indicate 50 nm.

837

838 Figure 6: Functional role of the association of HBV with lipoproteins

(A) HepG2-NTCP cells were infected with high pure luciferase expressing recombinant HBV 839 in the presence or absence of FCS (left) or in the presence of serum from ApoE KO or control 840 841 mice (right). On day seven cell culture supernatants were analysed for luminescence 842 intensities. (B) Differentiated HepaRG-cells were incubated with an LDL-receptor blocking antibody (anti-LDL-R) either before or before and during HBV infection or four days after 843 infection. On day 12 post HBV infection HBeAg was determined in the cell supernatant by 844 ELISA and cccDNA was quantified in cell lysates by quantitative RT-PCR. (C-E) Isolated liver 845 macrophages were incubated for 1h with VP₅₉₄ in medium containing 10% human serum and 846 washed. In (C) 5 µg/ml chylomicron NBD-cholesterol was added for 2 hours, in (D) 2 µg/ml 847 HDL₄₈₈ was added for 1h before fixation. (E) Cells were fixed and stained for ApoA1. Merged 848 849 pictures show VP₅₉₄ in red, NBD-cholesterol, HDL₄₈₈, and ApoA1 staining in green, and nuclear staining with DAPI in blue. Scale bars indicate 1 µM **p<0.01; ***p<0.001; ****p<0.0001. 850

851

852 Fig 7: Recycling of HBV along intracellular transport pathways of free cholesterol.

(A-C) Monocyte derived macrophages were loaded for 16h with cholesterol using medium 853 containing 50 µg/ml acLDL, incubated with VP₅₉₄ containing medium for 1h and further 854 incubated for 4h with acLDL containing medium without VP₅₉₄. After fixation cells were stained 855 with filipin to detect free cholesterol. (A) Total cellular (total) and perinuclear (pn) areas of a 856 representative cell are indicated by dashed lines. The boxed area is exemplarily shown 857 enlarged below the main panels separately for each channel. Merged pictures show VP₅₉₄ in 858 red and filipin staining in green. Scale bar is 10 µm. (B, C) 5 µM U18666A was added to the 859 culture medium as indicated. (B) Representative vision fields of several macrophages. (C) 860 Relative fluorescence intensity (I) of filipin- and Alexa 594[®] in the cell periphery were calculated 861 by subtracting pn from total signals and multiplying these with the corresponding area to 862 quantify the content of free cholesterol and VP_{594} . The diagram gives the ratio of pn to 863 peripheral cholesterol (Filipin, dots) and VP₅₉₄ (triangles) in analysed cells. Scale bar is 10 µm 864 (A) or 100 µm (B). (D-E) THP macrophages were incubated with HBV in serum free medium 865 for 3h, washed and further cultured for 16h with 0,2% BSA containing medium only or medium 866 supplemented with 100 or 200 µg/ml HDL as indicated. (D) Supernatants of macrophages 867 were collected and analysed for HBsAg or (E) HBV-DNA content. (F) THP macrophages were 868 869 incubated with HBV in 0,2% BSA containing medium for 3h, washed and further cultured for

16h with 0,2% BSA containing medium only or supplemented with 25 μ g/ml ApoA1. (**G**) THP cells were incubated with HBV and 1 μ g/ml [3H]-cholesterol-chylomicrons in serum free medium (w/o) or medium containing 10% human serum. Cells incubated with neither HBV nor [3H]-cholesterol-chylomicrons were used as negative control (–). In cell lysates and supernatant, HBV-DNA was quantified by real time PCR, and [3H]-cholesterol content was determined by liquid scintillation counting. Mean values ± SD of four independent experiments are given.

877

878 Fig 8: HBV transport from liver macrophages into hepatocytes.

879 (A-E) Human liver tissue was perfused with medium containing VP₅₉₄ (shown in red) and 50% 880 human serum for 1h, followed by a 16h perfusion without HBV before fixation. DAPI staining 881 is shown in blue. All scale bars are 10 µm. (A) Immunofluorescence staining for CD68+ liver macrophages. The tissue shows liver sinuses with hepatocytes neighboured by several 882 883 CD68+-stained liver macrophages. The boxed area is shown as enlargement below the main panels separately for each channel and focuses on one liver macrophage located in a liver 884 885 sinus next to two hepatocytes. The dotted line indicates the circumference of one hepatocyte next to the macrophage. (B) Localization of HBV particles within one exemplary HepPar1+ 886 hepatocyte (green). Z-axis projections are given for each channel. (C) Quantification of HBV-887 888 positive CD68+ liver macrophages, CD68- cells and HepaPar1+ hepatocytes in ten random 889 vision fields at 200-fold magnification. Mean values ± SD. (D, E) Staining of neutral lipids with BODIPY493/503 shown in green within (**D**) a liver sinus with hepatocytes neighboured by two 890 liver macrophages or (E) focussing one hepatocyte and one liver macrophage indicated by 891 (Hep) and (KC), respectively. Hepatocytes (Hep) and liver macrophages (KC) are indicated. 892 (D) shows xy images at two different z-positions of the same vision field. (E) Boxed areas are 893 shown as enlargements for different z positions on the right. (F) Staining for SR-B1 (shown in 894 green). The arrow indicates VP₅₉₄ localised to SR-B1 positive plasma membranes. The area 895 896 highlighted by the white box is enlarged on the right. (G) Relative localization of VP₅₉₄ and CD68-positive liver macrophages (green) after 1h (left picture) and 17h perfusion (right 897 898 picture). For increased contrast, DAPI staining is shown in white. Hep: hepatocyte. All scale 899 bars are 10 µm.

900

901 Fig 9: Trans-infection of hepatocytes by HBV taken up by liver macrophages.

Primary liver macrophages (KC) and hepatocytes (PHH) were isolated from the same donors. 902 (A) KC were loaded with VP_{594} for 4h, thoroughly washed and co-cultured with hepatocytes 903 904 pre-labelled with 5-chloromethyl-fluorescein diacetate (CMFDA, green). One representative hepatocyte and liver macrophage each is shown. Lower panel shows Z-axis projection at the 905 dashed line. (B) Macrophage / hepatocyte mix culture was incubated with 2 µg/ml Alexa Fluor 906 907 488[®]-labelled acLDL (green) for 6h to stain macrophages. acLDL staining (left), phase contrast (middle) and overlay (right) are shown. The arrow indicates a membrane connection between 908 a macrophage and a hepatocyte. (C) Freshly isolated hepatocytes were incubated with 5 µM 909 Dil for 20 min, washed three times by centrifugation at 300g and seeded onto a culture of liver 910 macrophages from the same donor for 16h. A close connection that has established between 911 a hepatocyte and a macrophage is shown. The area highlighted by the white box is shown 912 enlarged below. Background fluorescence was acquired in a far-red fluorescence channel. 913 Merged pictures (right panel) show Dil in red and nuclear staining with DAPI in blue. (D) 914 915 Isolated KC were incubated with HBV for 6h at either 4°C or 37°C as indicated and washed, trypsinized, seeded and washed again before added to PHH. Widefield microscopy of 916


917 macrophage / hepatocyte mix cultures (left and middle panel) and pure liver macrophages 918 (right panel) at day 12 post infection. (E-G) Liver macrophages (KC) were incubated with HBV 919 for 6h at 4°C (dark gray bars) or 37°C (light grey bars) and washed, trypsinized, seeded and washed again before hepatocytes (PHH) were added. (E) Detection of HBV cccDNA in cell 920 lysates. (F) HBsAg and HBeAg were measured in co-culture media. (G) Negative control with 921 922 KC only. Values are mean ± SEM of two independent experiments, triplicates each. (H, J) 923 Primary macrophages were incubated with HBV in the presence or absence of 100 µM 924 Bulevertide or ant-HBsAg-antibodies (H) or with 5 µM U18666a (J), washed, trypsinized, 925 seeded and washed again before hepatocytes (PHH) were added. On day 12, HBV RNAs (H) or HBV cccDNA (J) were quantified. Values are mean ± SD (H) and ± SEM (J) of two (H) and 926 927 three (J) independent experiments, triplicates each. (I) Primary human hepatocytes only (left panel) or primary human macrophages (right panel) were incubated with 1x10⁸/ml virions. 928 Then, cells where either washed (hepatocytes only culture) or trypsinized and thoroughly 929 930 washed before hepatocytes were added to macrophages. On day 12 post infection, HBV cccDNA was quantified in cell lysates. Values are mean ± SEM of three independent 931 experiments, quadruplicates each. **p < 0.01, ***p < 0.001 and ****p < 0.0001. Scale bars are 932 933 10 μm (**A-C**) or 100 μm (**D**).


934


935

- 936
- 937


938 Supporting Information (text file): EXTENDED EXPERIMENTAL PROCEDURES











Е






































500

400


300

200

100

[H]-cholesterol/cpm

Filipin



F


0.4


0.3

0.1

-

00 0.2 6958H











(2) 2 8


oğram














Revised Manuscript in Word or RTF (no changes marked)

Click here to view linked References

Click here to access/download **Revised Manuscript in Word or RTF (no changes** marked) Esser, Cheng, Wettengel et al., 2023.docx Supplemental material (large tables and data sets only)

Click here to access/download **Supplemental material (large tables and data sets only)** Supporting information_extended experimental procedures.doc